Cover Image


Global Peptide Hormone Market & Pipeline Analysis

出版商 KuicK Research 商品編碼 328389
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
Back to Top
肽激素的全球市場和開發平台分析 Global Peptide Hormone Market & Pipeline Analysis
出版日期: 2015年04月01日 內容資訊: 英文

許多製藥企業認識到由於肽激素的市場化,各種疾病的治療可能性擴張。為此,對研究開發 (R&D) 活動投入大金額的資金,進行開發滿足未滿足需求的肽激素的新有效利用方法。關於部分荷爾蒙平衡治療劑,取得其功效、安全性的確認。還有各種肽激素障礙的治療選擇近幾年也開發出來。今後數年間,預期各種產品的臨床實驗、上市將進行。

本報告提供全球的肽激素的市場趨勢、臨床實驗進展相關分析、技術上的特性和主要的推動及阻礙市場要素、今後的市場趨勢預測、目前臨床實驗進展、主要的開發中產品 (共47種) 及已上市產品 (共24種) 的一覽、主要企業簡介等資訊彙整,為您概述為以下內容。

第1章 肽激素:簡介

第2章 肽激素療法的作用機制

第3章 全球肽激素市場概要

  • 目前市場方案
  • 肽激素的開發中產品的概要

第4章 全球肽激素市場動態

  • 有利的市場參數
  • 在企業化時的課題

第5章 全球肽激素市場未來展望

第6章 肽激素的臨床實驗平台產品:各企業、各適應症、各Phase

  • 不明
  • 研究階段
  • 前臨床
  • 第一階段
  • 第一/二階段
  • 第二階段
  • 第三階段
  • 登記前

第7章 已上市肽激素:各企業、各適應症

第8章 被中止、延期了的開發中產品:各企業、各適應症、各Phase

  • 中止
  • 市場撤退
  • 沒有開發報告
  • 延期

第9章 競爭情形

  • BioPartners
  • Boehringer Ingelheim
  • Eli Lily
  • Innovate Biopharmaceuticals
  • Merck
  • NovoNordisk
  • Par Pharmaceuticals
  • Pfizer
  • Roche
  • Sanofi
  • Tarix Pharmaceuticals



Human body consists of myriad of chemicals required for signaling, providing nutrients, proper growth and development. Hormones are one such chemical present in the body that plays a very important role in maintaining homeostasis. They are secreted from endocrine glands which are also known as duct less gland because hormones are directly secreted into the blood stream. Moreover, diversity could be observed in their molecular structure, chemical nature, functionality, site of secretion and action. Among hormones, peptide hormones form an important category consisting of short amino acid chains of varying sizes. They are secreted in miniscule quantities but their effect is profound on target tissue which may be distant to the site of secretion. Despite this fact, they are indispensible in nature and investigators are trying to increase understanding about their action mechanism to come forth with suitable therapeutics.

Diseases due to deficiency of peptide hormone have been observed by investigators and cure for some of them has been marketed across the globe. Investigators have found more than 50 types of hormones in body belonging to different classes having characteristic biochemical and biophysical properties. In this way, they offer huge commercialization potential but all of them don't have significant therapeutic benefits as compared to peptide hormones. They are customizable in nature due which they could be modulated according to the receptor molecules. As a result, their specificity increases several folds providing higher safety profile along with minimized side effects. Moreover, increased potency is among other benefits due to which lesser dosage is required for achieving higher therapeutic benefits. These favorable feature makes them a suitable candidate having significant therapeutic and commercialization potential in several disease categories.

Pharmaceutical companies have recognized the commercialization and therapeutic potential of peptide hormones for treating various diseases. As a result, they are investing more funds in research and development segment to develop novel therapeutics to fulfill high unmet medical necessities. Several peptide hormone drug development programs have been instigated by pharmaceutical companies which would help in generating significant revenues. Their administrations in several hormonal imbalances have shown proven safety and efficacy profiles leading to higher acceptance among patients. In past few years, new mechanisms have been deciphered by investigators that will offer more options to patients suffering from various peptide hormone disorders. It is expected that investigators would introduce innovative therapeutics in market due to increased funding in research and development segment.

Several years of knowledge has been gathered by investigators due to which market introduction of new peptide hormones is expected to take place in coming years. Progress has been made in improvement of peptide design and candidate molecule screening are undergoing through different phases of clinical trials. These innovative peptide hormones are expected to enter in global market in coming years for various disease categories. Due to significant therapeutic efficacy they are expected to compete effectively and erode profit of other therapeutics. Moreover, newer instruments are expected to be introduced for providing better control over quantity and quality of peptide hormones. Besides this their manufacturing capabilities are expected to increase several folds and introduction of superior technology will further allow the pharmaceutical manufacturers to achieve higher production at competitive pricing. With all these positive development, the future of peptide hormones seems to be optimistic.

“Peptide Hormones Market & Pipeline Insight 2015” Report Highlight:

  • Global Peptide Hormone Market Overview
  • Peptide Hormones Clinical Pipeline by Company, Indication & Phase
  • Marketed Peptide Hormones by Company & Indication
  • Peptide Hormones Clinical Pipeline: 47 Drugs
  • Majority Peptide Hormone in Phase-II Trials: 15 Drugs
  • Marketed Peptide Hormones: 24 Drugs
  • Global Peptide Hormone Market Future Prospects

Table of Contents

1. Introduction to Peptide Hormones

2. Mechanism of Peptide Hormone Therapy

3. Global Peptide Hormone Market Overview

  • 3.1. Current Market Scenario
  • 3.2. Peptide Hormones Pipeline Overview

4. Global Peptide Hormone Market Dynamics

  • 4.1. Favorable Market Parameters
  • 4.2. Commercialization Challenges

5. Global Peptide Hormone Market Future Prospects

6. Peptide Hormones Clinical Pipeline by Company, Indication & Phase

  • 6.1. Unknown
  • 6.2. Research
  • 6.3. Preclinical
  • 6.4. Phase-I
  • 6.5. Phase-I/II
  • 6.6. Phase-II
  • 6.7. Phase-III
  • 6.8. Preregistration

7. Marketed Peptide Hormones by Company & Indication

8. Discontinued & Suspended Pipeline by Company, Indication & Phase

  • 8.1. Discontinued
  • 8.2. Market Withdrawal
  • 8.3. No Development Reported
  • 8.4. Suspended

9. Competitive Landscape

  • 9.1. BioPartners
  • 9.2. Boehringer Ingelheim
  • 9.3. Eli Lily
  • 9.4. Innovate Biopharmaceuticals
  • 9.5. Merck
  • 9.6. NovoNordisk
  • 9.7. Par Pharmaceuticals
  • 9.8. Pfizer
  • 9.9. Roche
  • 9.10. Sanofi
  • 9.11. Tarix Pharmaceuticals

List of Figures

  • Figure 1-1: Properties of Peptide Hormone
  • Figure 1-2: Therapeutic Features of Peptide Hormones
  • Figure 1-3: Required Improvements for Peptide Hormones
  • Figure 2-1: Mechanism of Peptide Hormones
  • Figure 2-2: Mechanism of Insulin
  • Figure 2-3:Mechanism of Genotropin
  • Figure 2-4:Mechanism of Pitressin
  • Figure 2-5:Mechanism of Glucagon
  • Figure 3-1: Peptide Hormones Pipeline by Phase (%), 2015
  • Figure 3-2: Peptide Hormones Pipeline by Phase (Number), 2015
  • Figure 3-3: No Development Reported Peptide Hormones Pipeline by Phase (%), 2015
  • Figure 3-4: No Development Reported Peptide Hormones Pipeline by Phase (Number), 2015
  • Figure 3-5: Discontinued Peptide Hormones Pipeline by Phase (%), 2015
Back to Top